US Broker Ratings

Bristol-Myers Squibb (BMY): Analyst Ratings Signal 15.73% Upside Potential for Investors

Bristol-Myers Squibb Company (NYSE: BMY), a titan in the healthcare sector, operates at the forefront of the drug manufacturing industry. The company, headquartered in Princeton, New Jersey, has a storied..

Alnylam Pharmaceuticals (ALNY): Analyst Consensus Highlights Strong Buy Ratings Amid Robust Pipeline

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stands out in the biotechnology sector with its innovative approach to therapeutics, focusing on ribonucleic acid interference (RNAi) technology. With a market capitalization of $42.87..

CVS Health Corporation (CVS): Rating Update Reveals 30% Potential Upside, Making It a Buy for Investors

CVS Health Corporation (NYSE: CVS), a leading player in the healthcare plans industry, offers a compelling investment opportunity with notable growth potential. With a market capitalization of $76.79 billion, CVS..

Inspire Medical Systems, Inc. (INSP) Stock Analysis: Navigating a 61.65% Potential Upside

Inspire Medical Systems, Inc. (NYSE: INSP), a specialized player in the healthcare sector, offers investors a unique opportunity in the burgeoning field of medical devices aimed at treating obstructive sleep..

Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook with 20.96% Potential Upside

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is capturing the attention of investors with its significant growth prospects within the healthcare sector, particularly in the biotechnology industry. With a market capitalization of..

Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential 47% Upside Amid Biotech Innovations

Roivant Sciences Ltd. (NASDAQ: ROIV), a prominent player in the biotechnology sector, is capturing investor attention with its innovative approach to drug development and a potential upside of 47.19%, according..

Chemed Corp (CHE) Stock Analysis: Exploring a 29.59% Potential Upside in the Healthcare Sector

Chemed Corp (CHE), a prominent player in the healthcare sector, is capturing investor attention with a potential upside of 29.59%, according to current analyst ratings. Incorporated in 1970 and headquartered..

Verona Pharma plc (VRNA) Stock Analysis: Navigating the Biotech Terrain with a $8.95 Billion Market Cap

Investors eyeing Verona Pharma plc (NASDAQ: VRNA) are stepping into the dynamic world of biotechnology, where the company is making strides in developing treatments for respiratory diseases. With a market..

Prestige Consumer Healthcare (PBH) Stock Analysis: A 15% Upside Potential Amid Steady Growth

Prestige Consumer Healthcare Inc. (NYSE: PBH) stands as a noteworthy player in the Healthcare sector, specifically within the Drug Manufacturers – Specialty & Generic industry. With a market capitalization of..

Elanco Animal Health (ELAN) Stock Analysis: Investor Outlook Reveals 4.19% Potential Upside

For investors seeking opportunities in the healthcare sector, Elanco Animal Health Incorporated (ELAN) presents a compelling case. With a market capitalization of $7.41 billion, Elanco operates within the drug manufacturing..

BrightSpring Health Services, I (BTSG) Stock Report: A 36.89% Potential Upside Captures Investor Attention

BrightSpring Health Services, Inc. (NYSE: BTSG), a leading player in the healthcare sector, has been making waves with its promising growth metrics and a compelling potential upside. As a provider..

AbbVie Inc. (ABBV) Stock Analysis: Evaluating a 9.92% Potential Upside with Strong Buy Consensus

AbbVie Inc. (NYSE: ABBV), a titan in the healthcare sector, holds a formidable position in the drug manufacturing industry with a market capitalization of $336.11 billion. This Illinois-based biopharmaceutical company..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: A 50.91% Potential Upside Opportunity in Biotech

Akero Therapeutics, Inc. (NASDAQ: AKRO) is capturing investor attention with its cutting-edge approach to tackling metabolic diseases, a sector ripe for innovation. Headquartered in South San Francisco, California, Akero is..

Ionis Pharmaceuticals (IONS) Stock Analysis: Unveiling a 35% Upside Potential For Investors

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a key player in the biotechnology sector, is capturing investor attention with its robust drug pipeline and strategic partnerships. With a market capitalization of $6.72..

Sanofi (SNY) Stock Analysis: Exploring a 24% Upside with Strong Buy Ratings

Sanofi (SNY), a prominent player in the global healthcare sector, is drawing investor attention with its promising potential upside of 24%. The French pharmaceutical giant, with a market capitalization of..

Alkermes plc (ALKS) Investor Outlook: Unlocking a 58.58% Potential Upside

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector, operates within the specialty and generic drug manufacturing industry. Headquartered in Dublin, Ireland, Alkermes has carved out a significant..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Exploring a Promising 28.38% Potential Upside

In the dynamically evolving healthcare sector, Merit Medical Systems, Inc. (NASDAQ: MMSI) is emerging as a noteworthy player that individual investors should keep an eye on. With a market capitalization..

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Exploring a 10.5% Upside Potential

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) stands as a stalwart in the healthcare sector, specifically within the medical devices industry. With a market cap of $19.3 billion, this U.S.-based company..

Blueprint Medicines Corporation (BPMC) Stock Analysis: Navigating the Biotech Landscape with a 55.5% Revenue Growth Surge

Blueprint Medicines Corporation (NASDAQ: BPMC) stands out in the biotechnology sector with a market capitalization of $8.37 billion. As a company dedicated to developing precision therapies for genomically defined cancers..

Teleflex Incorporated (TFX) Stock Analysis: Poised for 23% Upside Potential with Strong Free Cash Flow

Teleflex Incorporated (NYSE: TFX) is navigating a challenging landscape in the healthcare sector, specializing in the development and supply of single-use medical devices. Despite recent headwinds, the company stands out..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds